ALC
Alcon Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · CH
$70.50
−2.19%Year over year
Reported trailing growth
- Revenue
- +7.8%
- EBITDA
- -26.8%
- EBIT
- -26.0%
- EPS
- -40.1%
- Free cash flow
- +9.1%
- Operating cash flow
- +9.6%
Forward estimates
Based on analyst estimates
- Revenue
- +8.0%
- EBITDA
- +99.0%
- EPS
- +192.8%
Three-year CAGR
- Revenue
- +6.1%
- EBITDA
- +9.8%
- EBIT
- +26.5%
- Net income
- +43.0%
- EPS
- +43.0%
- Free cash flow
- +50.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026